↓ Skip to main content

Cochrane Database of Systematic Reviews

Dehydroepiandrosterone for systemic lupus erythematosus

Overview of attention for article published in Cochrane database of systematic reviews, October 2007
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)

Mentioned by

facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
144 Mendeley
Title
Dehydroepiandrosterone for systemic lupus erythematosus
Published in
Cochrane database of systematic reviews, October 2007
DOI 10.1002/14651858.cd005114.pub2
Pubmed ID
Authors

David Crosbie, Corri Black, Linda McIntyre, Pamela Royle, Sian Thomas

Abstract

Systemic lupus erythematosus (SLE) is a chronic inflammatory, multisystem autoimmune condition. Dehydroepiandrosterone (DHEA) is a naturally occurring inactive steroid which may possess disease activity modifying properties as well as the ability to reduce flares and steroid requirements. To assess the effectiveness and safety of dehydroepiandrosterone compared to placebo in the treatment of people with systemic lupus erythematosus. We searched The Cochrane Library (Issue 2, 2006), MEDLINE, Pub Med, EMBASE, Science Citation Index and ISI Proceedings as well as searching web sites of Genelabs, FDA and EMEA. (Searches undertaken in June 2006 unless otherwise specified). We included randomised controlled trials of at least three months duration comparing DHEA to a placebo in people with SLE. Two review authors assessed quality and extracted data. From the seven RCTs identified (842 participants) to date there is 'gold' ranking evidence (www.cochranemsk.org) that DHEA: had little clinical effect on disease activity in those with mild/moderate disease (measured by SLEDAI or SLAM) but one study demonstrated evidence of stabilisation or improvement in 8.3% more patients than those treated with placebo; had a modest but clinically significant improvement in health related quality of life measured by Patient Global Assessment, estimated as 11.5% (11.5 mm on a 100 mm scale) by meta-analysis; resulted in a greater number of patients experiencing adverse events, particularly androgenic effects such as acne where patients risk was doubled when compared to placebo (RR 2.2; 95% CI 1.65 to 2.83) Studying effectiveness of DHEA for SLE is difficult, reflecting the problems of studying any treatment for a disease as complex as SLE. From the seven RCTs to date, there was evidence that DHEA had a modest but clinically significant impact on health related quality of life in the short term. Impact on disease activity was inconsistent, with DHEA showing no benefit over placebo in terms of change in SLEDAI in all but one of the 6 studies reporting this outcome. Long term outcomes and safety remain unstudied.

Mendeley readers

The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 144 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 27 19%
Researcher 16 11%
Student > Ph. D. Student 15 10%
Student > Bachelor 13 9%
Student > Doctoral Student 10 7%
Other 28 19%
Unknown 35 24%
Readers by discipline Count As %
Medicine and Dentistry 54 38%
Nursing and Health Professions 10 7%
Psychology 9 6%
Social Sciences 8 6%
Agricultural and Biological Sciences 5 3%
Other 17 12%
Unknown 41 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 March 2022.
All research outputs
#6,527,049
of 20,777,233 outputs
Outputs from Cochrane database of systematic reviews
#8,493
of 12,105 outputs
Outputs of similar age
#92,179
of 317,919 outputs
Outputs of similar age from Cochrane database of systematic reviews
#185
of 242 outputs
Altmetric has tracked 20,777,233 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 12,105 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 28.4. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,919 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 242 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.